Cyteir Therapeutics, Inc. Common Stock
CYT
CYT was delisted on the 15th of March, 2024.
37 hedge funds and large institutions have $34.6M invested in Cyteir Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less funds holding
Funds holding: 45 → 37 (-8)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
39% less capital invested
Capital invested by funds: $56.8M → $34.6M (-$22.2M)
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
CAAS Capital Management
New York
|
+$1.4M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$130K |
| 3 |
NM
Newtyn Management
New York
|
+$125K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$94K |
| 5 |
CC
Cannell Capital
Alta,
Wyoming
|
+$41.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$2.35M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.01M |
| 3 |
Morgan Stanley
New York
|
-$381K |
| 4 |
Renaissance Technologies
New York
|
-$210K |
| 5 |
D.E. Shaw & Co
New York
|
-$175K |
CYT Hedge Fund Activity: Q3 2022 in Review
37 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q3 2022, worth a combined $34.6M — down 39% from $56.8M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CYT and 2 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 11 added.
The largest buyer was CAAS Capital Management, adding an estimated $1.4M. The largest seller was Novo Holdings A/S, cutting an estimated $2.35M.
- 37 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q3 2022, down from 45 in Q2 2022.
- Funds reported $34.6M of Cyteir Therapeutics, Inc. Common Stock stock for Q3 2022, down 39% quarter-over-quarter.
- 2 funds opened new Cyteir Therapeutics, Inc. Common Stock positions in Q3 2022 and 10 closed out, a net change of -8 holders.
- The largest Cyteir Therapeutics, Inc. Common Stock buyer in Q3 2022 was CAAS Capital Management, an estimated $1.4M added.
- The largest Cyteir Therapeutics, Inc. Common Stock seller in Q3 2022 was Novo Holdings A/S, an estimated $2.35M sold.
Based on aggregated 13F filings for Q3 2022.